CORDENPHARMA BOULDER (CO, US)

Core Capabilities

  • >> Development & manufacturing of highly potent, cytotoxic & cytostatic APIs
  • >> Development to commercial quantities
  • >> Highly potent chromatography expertise

COMPLIANCE

  • >> Long history of successful US FDA inspections
  • >> PMDA inspected with zero critical observations
  • >> Inspected by TGA
  • >> Inspected by MHRA

Facility Legacy

CordenPharma Boulder is a world leader in the development and manufacturing of highly potent cytotoxic and cytostatic products, bringing expertise in process development, scale-up and cGMP manufacturing for highly potent APIs as well as experience in handling compounds below 10ng/m3 OEL.

HISTORY

  • >> 1991: Site founded as NaPro Biotherapeutics
  • >> 2003: Mayne Pharma acquired the facility
  • >> 2007: Became a member of Hospira due to the acquisition of Mayne
  • >> 2015: Pfizer acquired Hospira
  • >> 2017: Acquired by ICIG to become Corden Pharma Boulder
 

Managing Director

Brian McCudden

Corden Pharma Boulder

4876 Sterling Drive
Boulder 80301

Phone: +1 303 442-1926 Ext. 6623
Fax: +1 303 938-1255

Email Human Resources